The Lancet
2026-08-21 22:30 en
Atopic dermatitis remains one of the most burdensome inflammatory skin diseases worldwide, with a substantial effect on quality of life, sleep, mental health, and health-care use. Its population-level effect has been highlighted by the Global Burden of Disease Study analyses, in which atopic dermatitis ranks among the leading skin diseases by disability-adjusted life-years.1 Over the past decade, treatment has changed markedly. Biologics targeting type 2 inflammation and oral Janus kinase (JAK) inhibitors have expanded the therapeutic armamentarium, yet a relevant proportion of patients with…